Approval of the operating and financial review of Novartis AG, the financial statements of Novartis AG and the consolidated financial statements for the 2025 financial year
Advisory vote on the report on nonfinancial matters for the 2025 financial year
Discharge from liability of the members of the Board of Directors and the Executive Committee
Appropriation of available earnings of Novartis AG as per balance sheet and declaration of dividend for 2025
Reduction of share capital
Binding vote on the maximum aggregate amount of compensation for the Board of Directors from the 2026 Annual General Meeting to the 2027 Annual General Meeting
Binding vote on the maximum aggregate amount of compensation for the Executive Committee for the 2027 financial year
Advisory vote on the 2025 Compensation Report
Re-election of Giovanni Caforio as member and Board Chair
Re-election of Board of Director: Nancy C. Andrews
Re-election of Board of Director: Ton Buechner
Re-election of Board of Director: Patrice Bula
Re-election of Board of Director: Elizabeth Doherty
Re-election of Board of Director: Bridgette Heller
Re-election of Board of Director: Frans van Houten
Re-election of Board of Director: Elizabeth McNally
Re-election of Board of Director: Simon Moroney
Re-election of Board of Director: Ana de Pro Gonzalo
Re-election of Board of Director: John D. Young
Election of Board of Director: Charles Swanton
Re-election to the Compensation Committee: Patrice Bula
Re-election to the Compensation Committee: Bridgette Heller
Re-election to the Compensation Committee: Simon Moroney
Re-election to the Compensation Committee: John D. Young
Election to the Compensation Committee: Elizabeth McNally
Re-election of the auditor
Re-election of the Independent Proxy
General instructions in case of unannounced motions relating to items on the agenda and on new items on the agenda in accordance with Art. 704b of the Swiss Code of Obligations.